Clinical Trial Update: Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of low-molecular weight heparin for thromboprophylaxis in acutely ill medical patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Embolism | Phase 3 | Status: COMPLETED